Literature DB >> 10572152

Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.

S Johnson1, M H Samore, K A Farrow, G E Killgore, F C Tenover, D Lyras, J I Rood, P DeGirolami, A L Baltch, M E Rafferty, S M Pear, D N Gerding.   

Abstract

BACKGROUND: Large outbreaks of diarrhea caused by a newly recognized strain of Clostridium difficile occurred in four hospitals located in different parts of the United States between 1989 and 1992. Since frequent use of clindamycin was associated with the outbreak in one of the hospitals, we examined the resistance genes of the epidemic-strain isolates and studied the role of clindamycin use in these outbreaks.
METHODS: Case-control studies were performed at three of the four hospitals to assess the relation of the use of clindamycin to C. difficile-associated diarrhea. All isolates of the epidemic strain and representative isolates of other strains identified during each outbreak were tested for susceptibility to clindamycin. Chromosomal DNA from these representative isolates was also analyzed by dot blot hybridization and amplification with the polymerase chain reaction (PCR) with the use of probes and primers from a previously described determinant of erythromycin resistance - the erythromycin ribosomal methylase B (ermB) gene - found in C. perfringens and C. difficile.
RESULTS: In a stratified analysis of the case-control studies with pooling of the results according to the Mantel-Haenszel method, we found that the use of clindamycin was significantly increased among patients with diarrhea due to the epidemic strain of C. difficile, as compared with patients whose diarrhea was due to nonepidemic strains (pooled odds ratio, 4.35; 95 percent confidence interval, 2.02 to 9.38; P<0.001). Exposure to other types of antibiotics or hospitalization in a surgical ward was not significantly associated with the risk of C. difficile-associated diarrhea due to the epidemic strain. All epidemic-strain isolates were highly resistant to clindamycin (minimal inhibitory concentration, >256 microg per milliliter). DNA hybridization and PCR analysis showed that all these isolates had an ermB gene, which encodes a 23S ribosomal RNA methylase that mediates resistance to macrolide, lincosamide, and streptogramin antibiotics. Only 15 percent of the nonepidemic strains were resistant to clindamycin.
CONCLUSIONS: A strain of C. difficile that is highly resistant to clindamycin was responsible for large outbreaks of diarrhea in four hospitals in different states. The use of clindamycin is a specific risk factor for diarrhea due to this strain. Resistance to clindamycin further increases the risk of C. difficile-associated diarrhea, an established complication of antimicrobial use.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10572152     DOI: 10.1056/NEJM199911253412203

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  96 in total

Review 1.  Molecular detection of antimicrobial resistance.

Authors:  A C Fluit; M R Visser; F J Schmitz
Journal:  Clin Microbiol Rev       Date:  2001-10       Impact factor: 26.132

2.  Aliens, anaerobes, and the lung!

Authors:  Paul Marik
Journal:  Intensive Care Med       Date:  2003-07       Impact factor: 17.440

3.  Clostridium difficile infection in hospitals: risk factors and responses.

Authors:  Thomas J Louie; Jon Meddings
Journal:  CMAJ       Date:  2004-07-06       Impact factor: 8.262

4.  An enhanced DNA fingerprinting service to investigate potential Clostridium difficile infection case clusters sharing the same PCR ribotype.

Authors:  Warren N Fawley; Mark H Wilcox
Journal:  J Clin Microbiol       Date:  2011-09-28       Impact factor: 5.948

5.  The Role of the Intestinal Tract As a Source for Transmission of Nosocomial Pathogens.

Authors:  Usha Stiefel; Curtis J Donskey
Journal:  Curr Infect Dis Rep       Date:  2004-12       Impact factor: 3.725

6.  How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile?

Authors:  Thomas J Louie
Journal:  CMAJ       Date:  2005-10-25       Impact factor: 8.262

7.  Horizontal transfer of erythromycin resistance from Clostridium difficile to Butyrivibrio fibrisolvens.

Authors:  Patrizia Spigaglia; Fabrizio Barbanti; Paola Mastrantonio
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

8.  Antimicrobial susceptibility pattern of Clostridium difficile and its relation to PCR ribotypes in a Swedish university hospital.

Authors:  Olle Aspevall; Annika Lundberg; Lars G Burman; Thomas Akerlund; Bo Svenungsson
Journal:  Antimicrob Agents Chemother       Date:  2006-05       Impact factor: 5.191

Review 9.  Review: Clostridium difficile-associated disorders/diarrhea and Clostridium difficile colitis: the emergence of a more virulent era.

Authors:  Perry Hookman; Jamie S Barkin
Journal:  Dig Dis Sci       Date:  2007-02-16       Impact factor: 3.199

Review 10.  A review of the economics of treating Clostridium difficile infection.

Authors:  Kari A Mergenhagen; Amy L Wojciechowski; Joseph A Paladino
Journal:  Pharmacoeconomics       Date:  2014-07       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.